P-tau levels detected via ELISA had been the mainstay of p-tau measurements, with CSF p-tau231 having a reported sensitivity of 90.2% and specificity and 80.0% in discriminating between AD and non-AD disorders [81]. This evidence concerns the gene MAPT and Alzheimer disease.